Literature DB >> 16946555

CYP2C19 genetic polymorphism in Thai, Burmese and Karen populations.

Wichittra Tassaneeyakul1, Werawath Mahatthanatrakul, Kanokporn Niwatananun, Kesara Na-Bangchang, Arporn Tawalee, Nathawut Krikreangsak, Utaiwan Cykleng, Wongwiwat Tassaneeyakul.   

Abstract

The genetic polymorphism of CYP2C19 was examined in three Southeast Asian populations. This study was conducted in 774 Thais, 127 Burmeses and 131 Karens. Genomic DNA was extracted from leucocytes and analyzed by the PCR-RFLP technique. Genotype analysis revealed that the allele frequencies of CYP2C19*1, CYP2C19*2 and CYP2C19*3 in the Thais were 0.68, 0.29 and 0.03, respectively, and those of the Burmese population were 0.66, 0.30 and 0.04, respectively. For Karens, the minority ethnic in Mynmar, the allele frequencies of CYP2C19*1, CYP2C19*2 and CYP2C19*3 were 0.71, 0.28 and 0.01, respectively. The prevalence of PM estimated from genotype data among these three ethnic populations were 9.2%, 11.0%, and 8.4%, respectively. The PM phenotype and the frequencies of CYP2C19 defective alleles, particularly CYP2C19*3 among these three Southeast Asian ethnics appeared to be lower than other Asian populations. Lower prevalence of CYP2C19 PM suggests that these ethnics may have different capacity to metabolize drugs that are substrates of CYP2C19. Certain drug dosage regiments should be considered differently for Asian populations.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16946555     DOI: 10.2133/dmpk.21.286

Source DB:  PubMed          Journal:  Drug Metab Pharmacokinet        ISSN: 1347-4367            Impact factor:   3.614


  13 in total

1.  Comparison of genetic variation in drug ADME-related genes in Thais with Caucasian, African and Asian HapMap populations.

Authors:  Jiraphun Jittikoon; Surakameth Mahasirimongkol; Angkana Charoenyingwattana; Usa Chaikledkaew; Pramote Tragulpiankit; Supachoke Mangmool; Wimala Inunchot; Chayapol Somboonyosdes; Nuanjun Wichukchinda; Pathom Sawanpanyalert; Yijing He; Howard L McLeod; Wasun Chantratita
Journal:  J Hum Genet       Date:  2015-10-01       Impact factor: 3.172

Review 2.  Interethnic variation of CYP2C19 alleles, 'predicted' phenotypes and 'measured' metabolic phenotypes across world populations.

Authors:  I Fricke-Galindo; C Céspedes-Garro; F Rodrigues-Soares; M E G Naranjo; Á Delgado; F de Andrés; M López-López; E Peñas-Lledó; A LLerena
Journal:  Pharmacogenomics J       Date:  2015-10-27       Impact factor: 3.550

3.  Genetic polymorphism of CYP2C19 in Maharashtrian population.

Authors:  Yogita Ghodke; Kalpana Joshi; Yashendra Arya; Anjali Radkar; Aditi Chiplunkar; Pooja Shintre; Bhushan Patwardhan
Journal:  Eur J Epidemiol       Date:  2007-11-03       Impact factor: 8.082

4.  Pharmacogenetics of cyclophosphamide and CYP2C19 polymorphism in Thai systemic lupus erythematosus.

Authors:  Pintip Ngamjanyaporn; Ammarin Thakkinstian; Oravan Verasertniyom; Porntip Chatchaipun; Monchand Vanichapuntu; Kanokrat Nantiruj; Kitti Totemchokchyakarn; John Attia; Suchela Janwityanujit
Journal:  Rheumatol Int       Date:  2010-04-01       Impact factor: 2.631

5.  Genetic Polymorphism of Cytochrome p450 (2C19) Enzyme in Iranian Turkman Ethnic Group.

Authors:  Robabeh Ghiyas Tabari; Abdoljalal Marjani; Ogholdondy Agh Ataby; Azad Reza Mansourian; Nader Mansour Samai
Journal:  Oman Med J       Date:  2013-07

6.  Thiopurine S-methyltransferase pharmacogenetics: functional characterization of a novel rapidly degraded variant allozyme.

Authors:  Qiping Feng; Suda Vannaprasaht; Yi Peng; Susothorn Angsuthum; Yingyos Avihingsanon; Vivien C Yee; Wichittra Tassaneeyakul; Richard M Weinshilboum
Journal:  Biochem Pharmacol       Date:  2009-11-27       Impact factor: 5.858

7.  CYP2C19 polymorphisms in the Thai population and the clinical response to clopidogrel in patients with atherothrombotic-risk factors.

Authors:  Chonlaphat Sukasem; Ramaimon Tunthong; Montri Chamnanphon; Siwalee Santon; Thawinee Jantararoungtong; Napatrupron Koomdee; Santirhat Prommas; Apichaya Puangpetch; Prin Vathesatogkit
Journal:  Pharmgenomics Pers Med       Date:  2013-08-22

8.  Association of CYP2C19*2 and *3 genetic variants with essential hypertension in Koreans.

Authors:  Dong-Jik Shin; Jisun Kwon; Ah-Ram Park; Yousun Bae; Eun-Soon Shin; Sungha Park; Yangsoo Jang
Journal:  Yonsei Med J       Date:  2012-11-01       Impact factor: 2.759

9.  Clinical Application of CYP2C19 Pharmacogenetics Toward More Personalized Medicine.

Authors:  Su-Jun Lee
Journal:  Front Genet       Date:  2013-02-01       Impact factor: 4.599

10.  Genotype-phenotype analysis of CYP2C19 in healthy saudi individuals and its potential clinical implication in drug therapy.

Authors:  Leena H Saeed; Ahmed Y Mayet
Journal:  Int J Med Sci       Date:  2013-08-30       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.